ANN ARBOR, Mich., August 13, 2024--(BUSINESS WIRE)--ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^?), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for August 14, 2024.

The Company will file its quarterly report on form 10-Q with the SEC as regularly scheduled in the coming days. A press release summarizing its financial and operating results for the second quarter ending on June 30, 2024, will be issued on the day of the call.

Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the start of the call. Those unable to pre-register may participate by dialing (844) 868-8846 (U.S.) or (412) 317-5465 (International). A webcast of the call can also be accessed at ENDRA’s Investor Relations page and here.

A telephone replay will be available until August 29, 2024 by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and providing the passcode 5567407. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^?), a ground-breaking technology that characterizes tissue similar to an MRI, but at 1/40^th the cost and at the point of patient care. TAEUS^? is designed to work in concert with the more than 700,000 ultrasound systems in use globally today. TAEUS^? is initially focused on the non-invasive assessment of fatty tissue in the liver. Steatotic liver disease (SLD, formerly known as NAFLD-NASH) is a chronic liver disease spectrum that affects over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS^?, including non-invasive visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240813212894/en/

Contacts

Company:
Richard Jacroux
Chief Financial Officer
[email protected]
www.endrainc.com

Investor Relations:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
[email protected]